Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

US insulin pricing dispute

- PMLiVE

Keeping it in the family pays dividends

How playing the long game works for family-held and foundation firms through boom and bust

Deal Watch January 2017

Actelion, Johnson & Johnson, Sanofi, Takeda and more feature in this month's pharma deals round-up

- PMLiVE

Denmark pitches for EMA, with help from ex Novo Nordisk CEO

Lars Rebien Sørensen to serve as special envoy to promote Danish candidacy

- PMLiVE

Novo Nordisk invests £115m in Oxford diabetes unit

But Danish pharma company admitted Brexit had made it a harder decision

Deal Watch December 2016

Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up

Novo signs personalised digital health deal in diabetes

Will work with Glooko on jointly-developed and branded solutions

Sanofi reception

Sanofi launches insulin combo Soliqua in US

Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy

- PMLiVE

Pfizer/Opko’s long-acting growth hormone misses mark in trial

Previously forecast as a blockbuster product, hGH-CTP fails to show significant change

Key accounts – origins, responsibilities and differences

Good key account managers will know more about their account status than their customers do

Deal Watch November 2016

Actelion, Allergan, Johnson & Johnson, Novartis and more feature in this month's pharma deals round-up

Sanofi reception

FDA clears rival diabetes combos from Sanofi and Novo Nordisk

Xultophy set to launch in first half of 2017 while Soliqua is intended for January roll-out

- PMLiVE

Gilead’s hepatitis B virus treatment set for European approval

CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links